Jenner Institute, University of Oxford, Oxford, United Kingdom
David Pulido
Jenner Institute, University of Oxford, Oxford, United Kingdom
Francesca R. Donnellan
Jenner Institute, University of Oxford, Oxford, United Kingdom
Michelle L. Hill
Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom
Giacomo Gorini
Jenner Institute, University of Oxford, Oxford, United Kingdom
Hannah Davies
Jenner Institute, University of Oxford, Oxford, United Kingdom
Juliane Brun
Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom
Kirsty McHugh
Jenner Institute, University of Oxford, Oxford, United Kingdom
Lloyd D. W. King
Jenner Institute, University of Oxford, Oxford, United Kingdom
Katherine Skinner
Jenner Institute, University of Oxford, Oxford, United Kingdom
Kazutoyo Miura
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
Carole A. Long
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
Nicole Zitzmann
Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom
Simon J. Draper
Jenner Institute, University of Oxford, Oxford, United Kingdom
Reducing the mortality and morbidity associated with COVID-19 remains a global health priority. Vaccines have proven highly effective at preventing infection and hospitalization, but efforts must continue to improve treatment options for those who still become seriously ill.
